1 |
Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-1405.
DOI
|
2 |
Chiorean EG, Porter JM, Foster AE, Al Omari AS, Yoder CA, Fife KL, Strother RM, Murry DJ, Yu M, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res. 2008;14:1131-1137.
DOI
|
3 |
Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer. 2010;2:79-91.
DOI
|
4 |
Eadie MJ. Therapeutic drug monitoring--antiepileptic drugs. Br J Clin Pharmacol. 1998;46:185-193.
DOI
|
5 |
Sun J, Triggle DJ. Calcium channel antagonists: cardiovascular selectivity of action. J Pharmacol Exp Ther. 1995;274:419-426.
|
6 |
Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144:317-322.
DOI
|
7 |
Buckett L, Ballard P, Davidson R, Dunkley C, Martin L, Stafford J, McTaggart F. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis. 2000;151:41.
|
8 |
Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 2001;98:13919-13924.
DOI
|
9 |
Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012;87:E125-E128.
DOI
|
10 |
Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008;325:175-182.
DOI
|
11 |
Stevens R, Kakuda T, Bertz R, Mo H, Molla A, Rode R, Kempf D. Inhibitory quotient of protease inhibitors using a standardized determination of IC50. Paper presented at: 4th International Workshop on Clinical Pharmacology of HIV Therapy; 2003 Mar 27-29;Cannes, France.
|
12 |
Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K, Kirii Y. Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 2013;18:110-122.
DOI
|
13 |
Gustavsson S, Mardh S, Norberg L, Nyren O, Wollert S. Omeprazole, cimetidine, and ranitidine: inhibition of acid production in isolated human parietal cells. Scand J Gastroenterol. 1985;20:917-921.
DOI
|
14 |
Bastaki SM, Chandranath I, Garner A. Comparison of five antisecretory agents acting via gastric -ATPase. J Physiol Paris. 2000;94:19-23.
DOI
|
15 |
Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther. 1993;266:829-835.
|
16 |
Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda K. Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J Pharmacol Exp Ther. 1992;263:1127-1132.
|
17 |
Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9:929-939.
DOI
|
18 |
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96:7563-7568.
DOI
|